Quadrivalent meningococcal conjugate vaccines

Vaccine. 2009 Jun 24;27 Suppl 2:B30-41. doi: 10.1016/j.vaccine.2009.05.003. Epub 2009 May 27.

Abstract

Neisseria meningitidis is an important cause of bacterial meningitis and septicaemia with most disease caused by meningococci bearing serogroups A, B, C, Y and W-135 polysaccharides. Monovalent serogroup C conjugate vaccines have become established in the immunisation programmes in many countries and the first quadrivalent meningococcal vaccine, containing the polysaccharides from 4 of the serogroups A, C, Y and W-135 meningococci conjugated to a protein carrier was licensed in the US in 2005. This vaccine and others in development offer the potential to broaden population protection against meningococcal disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Humans
  • Meningitis, Meningococcal / microbiology
  • Meningitis, Meningococcal / prevention & control*
  • Meningococcal Vaccines / immunology*
  • Neisseria meningitidis, Serogroup A / immunology
  • Neisseria meningitidis, Serogroup B / immunology
  • Neisseria meningitidis, Serogroup C / immunology
  • Neisseria meningitidis, Serogroup W-135 / immunology
  • Sepsis / microbiology
  • Sepsis / prevention & control*
  • United States
  • Vaccines, Conjugate / immunology

Substances

  • Meningococcal Vaccines
  • Vaccines, Conjugate